Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 4/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | MDM4 | O15151 | 2/20 | 0.54 |
| ▸ | TP53 | P04637 | 2/20 | 0.54 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.51 |
| ▸ | MDM2 | Q00987 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26160451 | 1.00 | CASP3 (0.57) | CASP3KMT2AMDM4TP53EPHX2 | |
| SCHEMBL29446045 | 1.00 | CASP3 (0.57) | CASP3KMT2AMDM4TP53EPHX2 | |
| SCHEMBL29356265 | 1.00 | CASP3 (0.57) | CASP3KMT2AMDM4TP53EPHX2 | |
| SCHEMBL29401309 | 1.00 | CASP3 (0.57) | CASP3KMT2AMDM4TP53EPHX2 | |
| SCHEMBL29564442 | 1.00 | CASP3 (0.57) | CASP3KMT2AMDM4TP53EPHX2 | |
| SCHEMBL29349978 | 1.00 | CASP3 (0.57) | CASP3KMT2AMDM4TP53EPHX2 | |
| SCHEMBL178736 | 1.00 | CASP3 (0.57) | CASP3KMT2AMDM4TP53EPHX2 | |
| SCHEMBL29508222 | 1.00 | CASP3 (0.57) | CASP3KMT2AMDM4TP53EPHX2 | |
| SCHEMBL29446029 | 1.00 | CASP3 (0.57) | CASP3KMT2AMDM4TP53EPHX2 | |
| SCHEMBL119044 | 1.00 | CASP3 (0.57) | CASP3KMT2AMDM4TP53EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 196 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112159461-B | Synthesis method of cetrorelix | 开封明仁药业有限公司 | 2023-03-10 | — | — | CN | claimed |
| CN-112159461-A | Synthesis method of cetrorelix | 开封明仁药业有限公司 | 2021-01-01 | — | — | CN | claimed |
| WO-2020252713-A1 | MODIFIED HYDROPHOBIC AUXILIARY MATERIAL, PREPARATION METHOD THEREFOR AND USE THEREOF | 浙江智达药业有限公司 | 2020-12-24 | — | — | WO | claimed |
| CN-112110834-A | Modified hydrophobic auxiliary material and preparation method and application thereof | 浙江智达药业有限公司 | 2020-12-22 | — | — | CN | claimed |
| CN-102702327-B | Solid-liquid phase synthesis method for alarelin acetate | GL BIOCHEM SHANGHAI CO LTD | 2013-10-30 | — | — | CN | claimed |
| EP-4618952-A2 | METHODS FOR TREATING OBESITY WITH AN MC4R AGONIST | Rhythm Pharmaceuticals, Inc. (US) | 2025-09-24 | — | — | EP | disclosed |
| US-12098218-B2 | Process for the manufacture of degarelix and its intermediates | Fresenius Kabi iPSUM S.r.l (IT) | 2024-09-24 | — | — | US | disclosed |
| CN-114920804-B | Cetrorelix synthesis process capable of being directly used for pilot scale amplification | 厦门胜泽泰医药科技有限公司 | 2024-07-30 | — | — | CN | disclosed |
| WO-2024108198-A2 | METHODS OF TREATING OBESITY WITH AN MC4R AGONIST | RHYTHM PHARMACEUTICALS, INC. (US) | 2024-05-23 | — | — | WO | disclosed |
| EP-4309741-A1 | CYCLIC COMPOUND HAVING INHIBITORY EFFECT SELECTIVE FOR KRAS BUT NOT FOR HRAS AND NRAS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-01-24 | — | — | EP | disclosed |
| US-20230293716-A1 | ELASTASE-SUBSTRATE, PEPTIDE LINKER IMMUNOCONJUGATES, AND USES THEREOF | BOLT BIOTHERAPEUTICS, INC. (US) | 2023-09-21 | — | — | US | disclosed |
| EP-3810129-B1 | PCSK9 ANTAGONIST BICYCLO-COMPOUNDS | MERCK SHARP & DOHME LLC (US) | 2023-08-16 | — | — | EP | disclosed |
| US-20020049180-A1 | Compositions and methods for treating neoplastic disease using chemotherapy and radiation sensitizers | WU BIN (US) | 2002-04-25 | — | — | US | disclosed |
| WO-2001096523-A2 | POLYNUCLEOTIDES RELATED TO COLON CANCER | CHIRON CORPORATION (US) | 2001-12-20 | — | — | WO | disclosed |
| WO-2001091739-A2 | COMPOSITIONS AND METHODS FOR TREATING NEOPLASTIC DISEASE USING CHEMOTHERAPY AND RADIATION SENSITIZERS | CHIRON CORPORATION (US) | 2001-12-06 | — | — | WO | disclosed |
| CN-1309634-A | Hydrazine derivs. | HOFFMANN LA ROCHE (CH) | 2001-08-22 | — | — | CN | disclosed |
| WO-2001010827-A1 | ARYLSULFONAMIDO-SUBSTITUTED HYDROXAMIC ACID DERIVATIVES | NOVARTIS AG (CH) | 2001-02-15 | — | — | WO | disclosed |
| US-6018020-A | VIRICIDES WHICH ARE PROTEASE INHIBITORS AGAINST HEPATITIS C AND HEPATITIS G | HOFFMAN-LA ROCHE INC. (US) | 2000-01-25 | — | — | US | disclosed |
| EP-0941233-A2 | ANTIVIRAL PEPTIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 1999-09-15 | — | — | EP | disclosed |
| WO-1998022496-A2 | ANTIVIRAL PEPTIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 1998-05-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230293716-A1 | ELASTASE-SUBSTRATE, PEPTIDE LINKER IMMUNOCONJUGATES, AND USES THEREOF | SERPINB1, ELANE, CELA1 | CASP3 2109/4885KMT2A 4374/4885MDM4 2298/4885 |
| US-12098218-B2 | Process for the manufacture of degarelix and its intermediates | ANPEP, DNPEP, NPPA | CASP3 3415/4885KMT2A 1638/4885MDM4 123/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.